CEDAR KNOLLS, N.J.,
July 7, 2020 /PRNewswire/ -- MYOS
RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a
biotherapeutics and bionutrition company and the owner of
Fortetropin®, a proprietary bioactive composition
derived from fertilized egg yolk that helps build lean
muscle, announced today, the publication of
a study that evaluated the impact of Fortetropin
on the rate of muscle protein synthesis in older adults. The
peer reviewed study titled, "Effects of
Fortetropin® on the rate of muscle protein synthesis in
older men and women: a randomized, double blinded,
placebo-controlled study," published in the Journal of
Gerontology: Medical Sciences, reports results from a
randomized, double-blind, placebo-controlled human clinical study
involving 10 men and 10 women (60-75 years of age) conducted by
researchers at the University of California,
Berkeley and the University of
Arkansas for Medical Sciences. The study can be found
here: https://doi.org/10.1093/gerona/glaa162.
In this clinical study, the 20 men and women consumed either
Fortetropin or a macronutrient-matched placebo for 21 days along
with daily doses of a heavy water tracer. After 21 days, a muscle
biopsy was collected from each subject and analyzed to determine
the rate of synthesis of multiple muscle proteins. For subjects who
received Fortetropin, the average muscle protein synthesis rate was
significantly (18%) higher compared to the placebo group.
In a recent article published in Science Magazine,
researchers at Johns Hopkins University
highlighted the severe impact that COVID-19 has on muscle loss
(https://www.sciencemag.org/news/2020/04/survivors-severe-covid-19-beating-virus-just-beginning).
Japanese researchers have reported that low muscle mass is a
predictor of 90-day mortality in elderly patients who were
hospitalized for pneumonia. Researchers at the University of Texas Health Sciences Center,
Houston reported that low muscle
mass is associated with reduced ICU survival in elderly
patients. Pneumonia is a serious complication of
COVID-19. Many COVID-19 patients in serious condition require
treatment in the ICU, which in some cases includes mechanical
ventilation. Loss of muscle mass during treatment in the ICU
is rapid, substantial, and characterized by a large decrease in the
rate of muscle protein synthesis.
"The impact of sarcopenia on COVID-19 survival is not well
understood at this point as few studies have been published,"
stated Dr. William J. Evans, Adjunct
Professor of Nutrition, University of
California, Berkeley, a key opinion leader in sarcopenia and
the principal investigator of the human clinical study on
Fortetropin. "However, based on what we understand about the
causes of rapid loss of muscle, I would expect that stimulating the
synthesis of new proteins in the muscle of elderly patients will
result in increased muscle mass and better outcomes relative to
elderly patients with sarcopenia," added Dr. Evans.
Muscle loss represents one of the most important causes of
functional decline and loss of independence in older adults.
Age-related muscle loss (sarcopenia) is commonly observed in many
older adults and is also characterized by a decrease in the rate of
muscle protein synthesis. In addition, low muscle mass is
associated with increased risk of hip fracture, disability, and
mortality. Fortetropin was shown to increase the average muscle
protein synthesis rate, providing the potential to improve muscle
health among older adults. There are no approved pharmacological
options available to address age-related muscle loss. Geriatricians
commonly manage this through lifestyle interventions such as diet
and exercise.
"This study shows Fortetropin's remarkable potential for
managing age-related muscle loss in older adults. The results
from this clinical study will form the cornerstone of
MYOS' 'Healthy Aging' Business," commented
Joseph Mannello, Chief Executive
Officer of MYOS. "In May 2020,
we announced a commercial partnership with BodyLogicMD, one of the
largest nationwide networks of anti-aging medical practices in the
United States. As part of this partnership, we codeveloped a
Fortetropin-based nutrition product, BodyLogicMD Muscle Health
Formula with BodyLogicMD that will leverage results from this
publication along with four other peer reviewed studies that have
been published to date on Fortetropin," added Mr. Mannello.
"Fortetropin clearly has a robust effect on the rate of muscle
protein synthesis in older adults. It is rare for a nutrition
product to show such a consistent and positive effect. We look
forward to continued scientific collaboration with MYOS," stated
Dr. Evans.
About MYOS RENS Technology Inc.
MYOS RENS Technology
Inc. (MYOS), "The Muscle Company®", is a Cedar Knolls, NJ-based advanced nutrition
company that develops and markets products that improve muscle
health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size, lean body mass, and reduce muscle atrophy.
MYOS believes Fortetropin has the potential to redefine existing
standards of physical health and wellness and produces muscle
health support products featuring Fortetropin under the names of
Yolked®, Physician Muscle Health
Formula®, MYOS Canine Muscle
Formula® (Regular & Vet Strength), and
Qurr®. For more information, please visit
www.myosrens.com.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the success of our products,
including Yolked®, Physician Muscle
Health Formula®, MYOS Canine Muscle Formula®,
Qurr®, and MYOS Enteral
Nutrition Formula™, the success of our research and
development, the results of the clinical evaluation
of Fortetropin® and its effects,
including the results discussed above, the ability to enter into
new partnership opportunities and the success of our existing
partnerships, the ability to generate revenue and cash flow from
sales of our products, the ability to increase our revenue and
gross profit margins, the ability to achieve a sustainable,
profitable business, the effect of economic conditions, the ability
to protect our intellectual property rights, competition from other
providers and products, the continued listing of our securities on
the Nasdaq Stock Market, risks in product development, our ability
to raise capital to fund continuing operations, and other factors
discussed from time to time in our filings with the
Securities and Exchange Commission. We undertake no obligation to
update or revise any forward-looking statement for events or
circumstances after the date on which such statement is made except
as required by law.
Investor Relations:
MYOS RENS Technology
Joanne Goodford
Phone: 973-509-0444
Email: jgoodford@myoscorp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/university-of-california-berkeley-researchers-publish-clinical-results-reporting-that-fortetropin-increased-the-rate-of-muscle-protein-synthesis-in-older-adults-301088717.html
SOURCE MYOS RENS Technology
